Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Sipuleucel-T in Castration-Resistant Prostate Cancer

May 28th 2014

Radium-223: Treatment Considerations

May 28th 2014

Antiandrogens-Differences and Sequencing

May 28th 2014

Treating mCRPC with Newer Hormonal Agents

May 28th 2014

Oral Hormonal Agents for mCRPC

May 28th 2014

Treating Symptomatic Bone Metastatic CRPC

May 28th 2014

Multidisciplinary Approach to mCRPC Treatment

May 28th 2014

Evolution of Treatment for mCRPC

May 28th 2014

Biomarkers in the Management of Prostate Cancer

May 28th 2014

Biopsy, Biomarkers, and Imaging in Prostate Cancer

May 28th 2014

Prognostic Biomarker Tests for Prostate Cancer

May 28th 2014

Antiandrogen Monotherapy for mCRPC

May 28th 2014

Preventing SREs in Prostate Cancer

May 28th 2014

Role of Imaging in M0 CRPC

May 28th 2014

NCCN and AUA Prostate Cancer Guidelines

May 28th 2014

AUA Castration-Resistant Prostate Cancer Guidelines

May 28th 2014

Introduction: Therapeutic Advances in mCRPC

May 28th 2014

Dr. Shore on a Long-Term Safety Analysis of the COU-AA-302 Study

May 23rd 2014

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, Myrtle Beach, discusses a long-term safety analysis of the COU-AA-302 study, which he presented at the 2014 AUA Annual Meeting.

Dr. Kapoor Discusses the Inclusion of Radium-223 in AUA Guidelines for CRPC

May 21st 2014

Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).

PSA Growth Rate May Help Identify Aggressive Prostate Cancer Early

May 21st 2014

Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.